團結起來 各州
證券 和交易所佣金
華盛頓，特區。20549
表格
(標記一個)
| 根據1934年證券交易法第13或15(d)條規定的季度報告 |
截至季度結束
或者
| 根據1934年證券交易所法第13或15（d）節，報告過渡期從 到 |
委員會文件號
（符合其憲章規定的準確名稱）
（住所的州或其他司法轄區 文件號碼） |
（國稅局僱主 (主要 執行人員之地址) | |
| (主要 執行人員之地址) | (郵政 編 碼) |
註冊人的電話號碼，包括區號：(585)768-2513
根據法案第12(b)節註冊的證券:
| 每一類別的名稱 | 交易符號: |
在每個交易所註冊的名稱 | ||
| 股 股票市場 有限責任公司 | ||||
| 股 股票市場 有限責任公司 |
請在複選框中表明註冊者是否：（1）在過去的12個月內（或更短的時間段，註冊者應當提交此類報告）已經提交所有根據證券交易所法第13或第15（d）款所需提交的報告；並且（2）在過去的90天內一直受到這類提交要求的影響。 是 ☐
請勾選是否在過去12個月內（或更短時間）根據規則要求提交了要求提交的每個交互式數據文件。
在勾選標記處表示註冊人是大型加速提交人、加速提交人、非加速提交人、小型報告公司還是新興增長公司。請參閱證券交易法120億條規則中「大型加速提交人」、「加速提交人」、「小型報告公司」和「新興增長公司」的定義。
| 大型加速文件提交人 | ☐ | 加速文件提交人 | ☐ | |||
| ☒ | 小型報告公司 | |||||
| 新興成長公司 |
如果
一家新興成長型公司，用勾號表示註冊人是否選擇不使用延長的過渡期來遵守規定
以及根據《交易法》第13（a）條規定的任何新的或修訂的財務會計準則。
請在覈對標記處註明註冊人是否爲空殼公司（如交易所法案12b-2條所定義）。是☐
截至2024年12月5日，有 每股普通股的面值爲$每股面值爲$13的本公司普通股股票於截至2023年9月30日和2022年9月30日三個月內的運營報告中，分別已發行並流通，股份均爲180,641,272股。
目錄
| 頁面 | ||
| 第一部分。 | 財務信息 | |
| 項目 1. | 基本報表 | |
| 截至2024年3月31日（未經審計）的合併簡式資產負債表，以及截至2023年12月31日的資產負債表 | 1 | |
| 未經審計的合併簡式損益表，截止到2024年和2023年3月31日的三個月 | 2 | |
| 未經審計的合併簡式臨時股本變動表和股東赤字，截止到2024年和2023年3月31日的三個月 | 3 | |
| 未經審計的合併現金流量表，截止至2024年3月31日和2023年3月31日的三個月數據 | 4 | |
| 基本報表未經審核簡明合併財務報表註腳 | 5 | |
| 項目 2. | 管理層對財務狀況和業績的討論與分析 | 15 |
| 項目 3. | 市場風險的定量和定性披露。 | 21 |
| 項目 4. | 內部控制及程序 | 21 |
| 第二部分。 | 其他資訊 | 22 |
| 項目 1. | 法律訴訟 | 22 |
| 項目 1A | 風險因素 | 22 |
| 項目 2. | 股票權益的未註冊銷售和資金用途 | 22 |
| 項目 3. | 優先證券違約 | 22 |
| 項目 4. | 礦業安全披露 | 22 |
| 項目 5. | 其他資訊 | 22 |
| 項目 6. | 展品 | 22 |
| 簽名 | 23 | |
| i |
第一部分—財務資訊
項目 1. 基本報表
ONEMEDNET 公司
簡明合併資產負債表
(以千為單位，股份和每股資料除外)
(未經審計)
三月 31日， 2024 | 2023年12月31日 | |||||||
| 資產 | ||||||||
| 流動資產: | ||||||||
| 現金及現金等價物 | $ | $ | ||||||
| 應收帳款，淨額 | ||||||||
| 預付費用及其他流動資產 | ||||||||
| 流動資產總額 | ||||||||
| 不動產及設備，淨額 | ||||||||
| 總資產 | $ | $ | ||||||
| 負債和股東權益不足額 | ||||||||
| 流動負債： | ||||||||
| 應付帳款及應計費用 | $ | $ | ||||||
| 遞延收入 | ||||||||
| 貸款延期 | ||||||||
| PIPE票據 | ||||||||
| 遞延的承銷商費用應付 | ||||||||
| 授信額度 | ||||||||
| 流動負債總額 | ||||||||
| 貸款，關聯方 | ||||||||
| 其他長期負債 | ||||||||
| 總負債 | ||||||||
| 承諾及不確定事項（附註12） | ||||||||
| 股東資本赤字： | ||||||||
| 普通股股本，面額$, 截至2024年3月31日和2023年12月31日授權的股份; 截至2024年3月31日和2023年12月31日已發行和流通的股份 | ||||||||
| 普通股，面值$; 授權股份數， 已發行股份數量和 截至2024年3月31日流通的股份，以及 截至2023年12月31日，已發行並流通的股份數量。 | ||||||||
| 資本溢額 | ||||||||
| 按成本覈算的庫藏股 和 截至2024年3月31日和2023年12月31日的股份，分別是 | ( | ) | ||||||
| 累積虧損 | ( | ) | ( | ) | ||||
| 股東權益的赤字為 | ( | ) | ( | ) | ||||
| 總負債及股東權益赤字 | $ | $ | ||||||
附註 附註為此未經審核簡明綜合財務報表之重要組成部分。
| 1 |
ONEMEDNET公司
精簡 合併損益表
(以千計，不含股票和每股數據)
(未經審計)
| 截至3月31日的三個月結束 | ||||||||
| 2024 | 2023 | |||||||
| 收入 | ||||||||
| 訂閱收入 | $ | $ | ||||||
| 網頁影像營業收入 | ||||||||
| 總營業收入 | ||||||||
| 營收成本 | ||||||||
| 毛利率 | ( | ) | ( | ) | ||||
| 運營費用 | ||||||||
| 一般和行政 | ||||||||
| 銷售和營銷 | ||||||||
| 研發 | ||||||||
| 總營業費用 | ||||||||
| 營業損失 | ( | ) | ( | ) | ||||
| 其他費用（收益），淨額 | ||||||||
| 利息支出 | ||||||||
| 認股權證公允價值變動 | ( | ) | ||||||
| PIPE票據公平值變動 | ( | ) | ||||||
| 可轉換應收票據公平價值變動 | ||||||||
| 存貨權證費用 | ||||||||
| 其他（收入）費用 | ( | ) | ||||||
| 其他費用總計，淨額 | ||||||||
| 淨虧損 | $ | ( | ) | $ | ( | ) | ||
| 每股收益: | ||||||||
| 普通股每股基本和稀釋淨損失 | $ | ) | $ | ) | ||||
| 基本和稀釋後的平均流通股本 | ||||||||
附註是這些未經審計的簡明綜合財務報表的組成部分。
| 2 |
ONEMEDNET公司
壓縮 綜合變動表的暫時性權益和股東赤字
(以千爲單位，除股票數據外)
(未經審計)
| 總計 | ||||||||||||||||||||||||||||||||||||||||
| A-2系列基金 | A-1輪 | 短期投資證券 | 額外的 | 總計 | ||||||||||||||||||||||||||||||||||||
| 優先股 | 優先股 | 股權 | 普通股 | 實收股本 | 累計 | 股東權益 | ||||||||||||||||||||||||||||||||||
| 股份 | 金額 | 股份 | 金額 | 金額 | 股份 | 金額 | 資本 | 虧損 | 虧損 | |||||||||||||||||||||||||||||||
| 截至2022年12月31日的餘額 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||
| 與可轉換票據一起發行OMN warrants | - | - | - | |||||||||||||||||||||||||||||||||||||
| 基於股票的薪酬費用 | - | - | - | |||||||||||||||||||||||||||||||||||||
| 淨虧損 | - | - | - | ( | ) | ( | ) | |||||||||||||||||||||||||||||||||
| 截至2023年3月31日的餘額 | $ | $ | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||||||
| 額外的 | 總計 | |||||||||||||||||||||||||||
| 普通股 | 庫藏股 | 實收股本 | 累計 | 股東權益 | ||||||||||||||||||||||||
| 股份 | 金額 | 股份 | 金額 | 資本 | 虧損 | 虧損 | ||||||||||||||||||||||
| 截至2023年12月31日的餘額 | $ | $ | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||||||
| 發行普通股以結清應支付的延期承銷費用 | - | |||||||||||||||||||||||||||
| 基於股票的薪酬費用 | - | - | ||||||||||||||||||||||||||
| 回購普通股 | - | ( | ) | ( | ) | ( | ) | |||||||||||||||||||||
| 淨虧損 | - | - | ( | ) | ( | ) | ||||||||||||||||||||||
| 截至2024年3月31日的餘額 | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | $ | ( | ) | |||||||||||||||
附註是這些未經審計的簡明綜合財務報表的組成部分。
| 3 |
ONEMEDNET公司
簡明綜合現金流量表
（以千爲單位）
(未經審計)
| 截至3月31日的三個月結束 | ||||||||
| 2024 | 2023 | |||||||
| 經營活動現金流量： | ||||||||
| 淨虧損 | $ | ( | ) | $ | ( | ) | ||
| 調整爲淨損失到經營活動現金流量淨使用： | ||||||||
| 折舊和攤銷 | ||||||||
| 基於股票的薪酬費用 | ||||||||
| 權證負債公允價值變動 | ( | ) | ||||||
| PIPE票據公平值變動 | ( | ) | ||||||
| CEBA貸款的豁免收益 | ( | ) | ||||||
| 非現金利息 | ||||||||
| 可轉換應收票據公平價值變動 | ||||||||
| 存貨權證費用 | ||||||||
| 經營性資產和負債的變化： | ||||||||
| 應收賬款 | ( | ) | ( | ) | ||||
| 預付費用及其他流動資產 | ( | ) | ( | ) | ||||
| 應付賬款和應計費用 | ||||||||
| 遞延收入 | ||||||||
| 用於經營活動的淨現金 | ( | ) | ( | ) | ||||
| 投資活動現金流量： | ||||||||
| 購買物業和設備 | ( | ) | ||||||
| 投資活動中使用的淨現金 | ( | ) | ||||||
| 融資活動的現金流： | ||||||||
| 股東貸款發行的收益 | ||||||||
| 信用額度借款的收益 | ||||||||
| CEBA貸款的償還 | ( | ) | ||||||
| 發行可轉換債券所得款項 | ||||||||
| 業務組合成本 | ( | ) | ||||||
| 融資活動提供的淨現金 | ||||||||
| 現金及現金等價物的淨增加（減少） | ( | ) | ||||||
| 期初現金及現金等價物餘額 | ||||||||
| 期末現金及現金等價物 | $ | $ | ||||||
| 非現金投資和籌資活動的補充披露: | ||||||||
| 發行普通股以結清應支付的延期承銷費用 | $ | $ | ||||||
| 回購普通股的考慮已包含在應付賬款和應計費用中 | $ | ( | ) | $ | ||||
附註是這些未經審計的簡明綜合財務報表的組成部分。
| 4 |
ONEMEDNET公司
筆記 至未經審計的簡明合併財務報表
1. 業務描述
組織 和業務描述
OneMedNet 公司（以下簡稱「公司」）是一家專注於數字醫療影像管理、 交易所和共享的醫療軟件公司。該公司於2015年11月20日在特拉華州成立。公司一直專注於創建簡化數字醫療影像管理、交易所和共享的解決方案。 公司有一家全資子公司OneMedNet Technologies （加拿大）有限公司，成立於2015年10月16日，依據不列顛哥倫比亞省的《商業公司法》註冊，功能貨幣爲加幣。公司的總部位於明尼蘇達州的伊甸草坪。
在2023年11月7日，Data Knights Merger Sub, Inc.（"Merger Sub"）是一家特拉華州公司，也是Data Knights Acquisition Corp.（"Data Knights"）的全資子公司，合併到OneMedNet Solutions Corporation（前身爲OneMedNet Corporation）（"Legacy ONMD"）中，Legacy ONMD作爲Data Knights的全資子公司存續（"業務合併"）。在業務合併完成後，Data Knights更名爲「OneMedNet Corporation。」
基礎 展示和合並的基礎
附帶的未經審計的壓縮合並基本報表已按照美國通用會計原則（"U.S. GAAP"）及證券交易委員會（"SEC"）對於中期報告的規則和規定準備。根據這些規則和規定，某些通常包含在按U.S. GAAP準備的基本報表中的註釋或其他財務信息已被壓縮或省略。未經審計的中期壓縮合並基本報表已與年度合併基本報表的準備基礎相同，並且，根據管理層的意見，反映了所有調整，這些調整僅包括爲公平呈現公司在所呈現中期的結果所必需的正常、經常性調整。截止到2024年3月31日的三個月運營結果並不一定代表2024年12月31日截止的年度結果或任何未來年度或中期的結果。
隨附的未經審計的臨時合併基本報表應與截至2023年12月31日的年度合併基本報表及相關附註一併閱讀，這些內容已在我們於2024年11月5日向美國證券交易委員會提交的《10-K表格（修訂稿）》中列出。
截至2023年10月的 未經審計的臨時合併基本報表包括本公司的全資子公司 OneMedNet Technologies (Canada) Inc. 所有重要的內部交易在合併中已被消除。
流動性 和持續經營
公司自成立以來一直產生經常性淨虧損，包括截至2024年3月31日和2023年3月31日的$
To continue in existence and expand its operations, the Company will be required to, and management plans to, raise additional working capital through an equity or debt offering and ultimately hopes to attain profitable operations to fulfill its operating and capital requirements for at least 12 months from the date of the issuance of the condensed consolidated financial statements. However, the Company may not be able to secure such financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may have rights, preferences and privileges senior to those of the Company’s existing stockholders. The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern. The Company’s continuation as a going concern is dependent upon its ability to continue receiving working capital cash payments and generating cash flow from operations.
| 5 |
Risks and uncertainties
The Company is subject to risks common to companies in the markets it serves, including, but not limited to, global economic and financial market conditions, fluctuations in customer demand, acceptance of new products, development by its competitors of new technological innovations, dependence on key personnel, and protection of proprietary technology.
Segment information
The Company operates in one operating segment and, accordingly, no segment disclosures have been presented herein.
2. Summary of Significant Accounting Policies
Except as described below, the accounting policies of the Company are set forth in Note 2 to the consolidated financial statements contained in the Form 10-K/A, and the accounting policies followed by the Company for interim financial reporting are consistent with the accounting policies therein.
Treasury stock
The Company records the repurchase of its common stock, par value $ per share (“Common Stock”) at cost on the trade date of the transaction. These shares are considered treasury stock, which is a reduction to stockholders’ equity. Treasury stock is included in authorized and issued shares but excluded from outstanding shares.
Emerging growth company status
The Company is an “emerging growth company”, as defined in the Jumpstart Our Business Startups Act of 2012 (“JOBS Act”). Under the JOBS Act, emerging growth companies can take advantage of an extended transition period for complying with new or revised accounting standards, delaying the adoption of these accounting standards until they would apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (1) is no longer an emerging growth company or (2) affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act.
Accounting pronouncements not yet adopted
In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures (Topic 740) (“ASU 2023-09”). ASU 2023-09 requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. ASU 2023-09 is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. The Company is currently evaluating the impact of adopting ASU 2023-09.
在2023年11月，FASB發佈了ASU No. 2023-07， 分部報告（主題 280）：報告服務部門（主題 280）變更披露方式，通過升級對意義重大的分部費用的披露來改進分部報告披露要求。該準則適用於 2023 年 12 月 15 日之後的財年和 2024 年 12 月 15 日之後的財年間隔期。該準則必須適用於財務報表中呈現的所有期間的追溯。該公司目前正在評估該標準對合並財務報表的影響。, 這項標準旨在增強細分披露，即使對於只有一個可報告細分的實體也是如此。特別是， 該標準將要求定期披露提供給首席運營決策maker的重要細分費用，幷包括在每個報告的細分利潤和損失的衡量中。該標準還要求按可報告細分披露所有其他細分項目以及其組成的描述。最後，該標準將要求披露首席運營決策maker的職稱和職位，並解釋首席運營決策maker如何利用報告的細分利潤或損失的衡量來評估細分績效以及決定如何分配資源。該標準適用於在2023年12月15日之後開始的年度期間，以及在2024年12月15日之後開始的年度期間內的中期。允許提前採用。公司目前正在評估該標準對其合併基本報表及附註的影響。
最近採納的會計準則
2023年12月，FASB發佈了ASU No. 2023-08， 無形資產-商譽和其他-加密資產（主題350-60）：對加密資產的會計處理和披露 (“ASU 2023-08”美國公證會計準則2023-08要求每個報告期對某些加密資產進行公允價值計量，公平價值變動反映在淨利潤中。修訂還要求披露每個重要加密資產的名稱、公允價值、持有單位和成本基礎，以及加密資產持有量的年度對賬。新指南適用於2024年12月15日之後開始的財政年度和這些財政年度內的中期時段，可以提前採納。公司選擇在2024年1月1日提前採納此指南。截至2024年3月31日的三個月結束日，公司採用美國公證會計準則2023-08對財務報表的整合未產生影響。
| 6 |
3. 可轉換債務
可轉換可轉讓票據
從2019年到2023年，公司向相關和不相關的投資者發行了多種可轉換票據，這些票據可以在下一次股權融資交易中轉換爲Legacy ONMD的股權證券（以下簡稱「可轉換票據」）。可轉換票據的利率爲
可轉換票據是爲了一般營運資金目的而發行的。公司選擇在ASC 825下的公允價值選項（「FVO」） 金融工具，用於其可轉換票據。在FVO選舉下，金融工具最初按其發行日估計的公允價值進行計量，並在每個報告期的日期按估計的公允價值進行定期重新計量。公允價值的估計調整作爲其他（收入）費用中的一項單行項目呈現在附帶的合併損益表中，標題爲可轉換債務公允價值變動.
在 2023年11月，所有可轉換承諾票據根據其與Data Knights和Legacy ONMD之間的業務合併的條款被轉換，並在2023年12月31日後不再存在。有關在2023年12月31日之前發行的可轉換承諾票據的所有其他詳細信息，請參見10-K/A表格。
管道 備註
在
2023年6月28日，
公司選定將其PIPE票據記入公允價值選擇權會計。估計的公允價值調整被呈現爲附帶的損益表中的一項其他（收入）費用淨額，標明爲PIPE票據公允價值變動。截至2024年3月31日和2023年12月31日，PIPE票據的公允價值爲$
股東貸款
在2024年1月，公司收到來自關聯方投資者的股東貸款總收益爲$
海倫娜 筆記
在2024年3月28日，公司 與Helena Global Investment Opportunities 1 Ltd.（「Helena」），Cayman Islands的一家顧問和投資者Helena Partners Inc.的關聯公司簽署了最終證券購買協議（「Helena SPA」），該協議提供了最多$
根據
海倫娜終止協議，公司向海倫娜發行了一份購買認股權證
| 7 |
4. Line of Credit
In
March 2024, the Company obtained a line of credit of $
5. Canadian Emergency Business Loan Act (“CEBA”)
During
December 2020, the Company applied for and received a $
6. Stockholders’ Deficit
Common Stock
就業務合併一事，Data Knights與承銷商（「EF Hutton」）達成協議，其中EF Hutton同意放棄在收盤時應支付的相關合並承銷費用（$
在2024年2月，公司與一位可轉債的前持有人簽署了一份股票回購協議，依據該協議，公司回購了 普通股的
優先股
截至2024年3月31日， 優先股發行或流通。所有舊版ONMD A-2系列優先股和A-1系列優先股股票已在業務組合中轉換爲普通股。有關2023年12月31日前發行的A-2系列優先股和A-1系列優先股的所有其他詳細信息，請參閱Form 10-K/A。
| 8 |
截至2024年3月31日和2023年3月31日的三個月，計算基本和攤薄每股淨虧損所使用的普通股加權平均發行股份數量是相同的。在計算截至2024年3月31日和2023年3月31日的三個月的攤薄每股淨虧損時，公司排除了以下潛在的稀釋性證券，因其影響將是反稀釋的，並且降低每個期間計算的每股淨虧損：
三個月 結束 3月31日 | ||||||||
| 2024 | 2023 | |||||||
| 購買普通股的期權 | ||||||||
| 未歸屬的限制性股票單位和獎勵 | ||||||||
| 普通股權證 | ||||||||
| A系列-1優先股 | ||||||||
| A-2系列優先股 | ||||||||
| 可轉換的可轉換票據 | ||||||||
| 總計 | ||||||||
| 截至三月三十一日的三個月 | ||||||||
| 2024 | 2023 | |||||||
| 營業成本 | $ | $ | ||||||
| 一般 和行政 | ||||||||
| 銷售與市場營銷 | ||||||||
| 研發成本 | ||||||||
| 總 基於股票的薪酬費用 | $ | $ | ||||||
股權 激勵計劃 – 摘要
在2023年，公司採用了OneMedNet Corporation 2022年股票激勵計劃（「2022計劃」）和 預留了相當於 2022計劃在業務合併關閉時立即生效，並取代了傳統的ONMD股票激勵計劃。
股權 激勵計劃 – 期權
截至2024年3月31日和2023年3月31日的三個月內，公司記錄的基於股票的補償費用爲$ 千和$ 千， 分別適用於其未行使的期權。
股權 激勵計劃 – 限制性股票單位（「RSU」）
For the three months ended March 31, 2024 and 2023, the Company recorded stock-based compensation expense of $ thousand and $ thousand, respectively, on its outstanding restricted stock units.
9. Stock Warrants
The Company has the following warrants outstanding for the periods presented:
| As of | ||||||||
March 31, 2024 | December 31, 2023 | |||||||
| Liability Classified Warrants | ||||||||
| Private Placement Warrants | ||||||||
| PIPE Warrants | ||||||||
| Subtotal | ||||||||
| Equity Classified Warrants | ||||||||
| Public Warrants | ||||||||
| Subtotal | ||||||||
| Grand Total | ||||||||
| 9 |
Convertible Promissory Notes Warrants
As
described in Note 3, the Company issued Convertible Promissory Notes Warrants in 2022 and 2023. The Convertible Promissory Notes
Warrants are classified as equity in accordance with ASC subtopic 815-40, Derivatives and Hedging - Contracts in Entity’s
Own Equity (“ASC 815-40”). The Company determined that the fair value of the combined instrument (inclusive of the
Convertible Promissory Notes) significantly exceeds the proceeds received; therefore, the Company concluded that the Convertible Promissory Notes Warrants are
most accurately portrayed as an issuance cost related to the Convertible Promissory Notes. This resulted in an expense of $
In
connection with the closing of the Business Combination on November 7, 2023, all Convertible Promissory Notes Warrants were cashless
exercised into shares of Legacy ONMD common stock and exchanged based on the appropriate conversion ratio for the Common Stock less an
exercise price of $
PIPE Warrants
In
conjunction with the issuance of the PIPE Notes described in Note 3, Data Knights also issued and sold to each of the Purchasers
warrants to purchase Common Stock at an exercise price of $
Private Placement Warrants
關於2023年11月7日業務合併的完成，公司承擔了
10. 公允價值衡量
下表列出了公司的資產和負債，這些資產和負債按照定期基礎計量公平價值，包括關聯方（以千計）。
| 2024年3月31日 | ||||||||||||||||
| 一級 | 二級 | 三級 | 總計 | |||||||||||||
| 負債： | ||||||||||||||||
| 認股權證 | $ | $ | $ | $ | ||||||||||||
| PIPE認股權 | ||||||||||||||||
| PIPE備忘錄 | ||||||||||||||||
| 總負債，按公允價值計量 | $ | $ | $ | $ | ||||||||||||
| 2023年12月31日 | ||||||||||||||||
| 一級 | 二級 | 三級 | 總計 | |||||||||||||
| 負債： | ||||||||||||||||
| 認股權證 | $ | $ | $ | $ | ||||||||||||
| PIPE認股權 | ||||||||||||||||
| PIPE 註記 | ||||||||||||||||
| 總負債，按公允價值計量 | $ | $ | $ | $ | ||||||||||||
| 10 |
下表展示了截至2024年3月31日的三個月期間，私人warrants、PIPE票據和PIPE warrants在公允價值下的變化（單位：千美元）：
| 三級展期： | 私人 認購權證 | 私有投資（PIPE） 附註 | 私有投資（PIPE） 認購權證 | |||||||||
| 2023年12月31日餘額 | ||||||||||||
| 公允價值變動 | ( | ) | ( | ) | ||||||||
| 2024 年 3 月 31 日餘額 | $ | $ | $ | |||||||||
私募 配售warrants和PIPE warren
定向增發認股權證和PIPE認股權證的總公允價值爲$
| 截至2024年3月31日， | ||||||||
| 2024 | ||||||||
| 私有投資（PIPE） | 私人 | |||||||
| 認購權證 | 認購權證 | |||||||
| 股票價格 | $ | $ | ||||||
| 行使價格 | $ | $ | ||||||
| 預期波動率 | % | % | ||||||
| 加權平均無風險利率 | % | % | ||||||
| 預期股息收益率 | ||||||||
| 預期期限（以年爲單位） | ||||||||
管道 備註
這些PIPE票據的估計公允價值是根據某些可能場景的聚合概率加權平均結果確定的。然後，這些結果的概率加權平均值的總和被折現回每個報告期，在每種情況下，基於估計的隱含折現率，按風險調整的折現率進行折現。鑑於與公司相關的事實模式和發展階段，折現率在估值期間保持不變。
PIPE票據的公允價值截至2024年3月31日爲$
11. 關聯方交易
PIPE票據和認股權證
Data
Knights在業務組合過程中發行並出售PIPE票據，這些票據可轉換爲普通股。 從PIPE票據籌集的總款項爲$
與PIPE票據的發行相關，公司還發行了總共
可轉換的應付票據和認股權證
如第3條所述，公司向相關方投資者發行了多種可轉換票據。與相關方的可轉換票據所募集的總收入爲$
| 11 |
Shareholder Loans
In
addition to the convertible shareholder loans described in Note 3, the Company also received gross proceeds of $
| As of | ||||||||
March 31, 2024 | December 31, 2023 | |||||||
| Shareholder loans – nonconvertible | $ | $ | ||||||
| Shareholder loans – convertible | ||||||||
| Accrued interest | ||||||||
| Total shareholder loans | $ | $ | ||||||
Loan Extensions
The
Company assumed Data Knights’ liabilities, which included existing loan extensions to related parties. The loan extensions were
to be either repaid in cash or, at the option of the lender, exchanged for a fixed amount of Common Stock at a price of $ per share
upon the closing of a business combination or a similar event. At the closing of the Business Combination, all lenders provided notice
to have their loans converted into shares upon the filing of a registration statement on Form S-1 with the SEC. As of March 31, 2024,
a registration statement has not yet been declared effective by the SEC, and a balance of $
12. Commitments and Contingencies
Lease Agreement
The
Company has a month-to-month lease for its headquarters space at a cost of $
Litigation
From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. Liabilities for loss contingencies arising from claims, assessments, litigation, fines, penalties, and other sources are recognized, if and when it is probable that a liability has been incurred and the amount can be reasonably estimated. The Company was not subject to any material legal proceedings during the three months ended March 31, 2024 and 2023.
13. Subsequent Events
The Company has evaluated subsequent events occurring through December 5, 2024, the date the condensed consolidated financial statements were issued, for events requiring recording or disclosure in the Company’s condensed consolidated financial statements.
Shareholder Loans
From
April 2024, through the date of this report, the Company received gross proceeds of $
Private Placements
As
described in Note 3, on June 14, 2024, the Company and Helena entered into the Helena Termination Agreement to terminate the Helena SPA
and related documents. Pursuant to the Helena Termination Agreement, the Company issued to Helena a warrant to purchase
| 12 |
On
July 23, 2024 and July 25, 2024, the Company entered into securities purchase agreements (the “Securities Purchase Agreements”)
with certain institutional investors in connection with the private placement of its Common Stock and pre-funded warrants with aggregate
gross proceeds of approximately $
Pursuant
to the Securities Purchase Agreements, the Company agreed to issue and sell to the investors shares of its Common Stock at
a price of $ per share, pre-funded warrants exercisable for
On
September 24, 2024, the Company entered into a securities purchase agreement (the “Follow-on SPA”) with an institutional
accredited investor in connection with the private placement of its Common Stock, warrants and pre-funded warrants with aggregate gross
proceeds of approximately $
Pursuant
to the Follow-on SPA, the Company agreed to issue and sell to the investor shares of its Common Stock at a price of $ per
share, warrants exercisable for shares of its Common Stock at an exercise price of $
Standby Equity Purchase Agreement
On
June 17, 2024, the Company entered into a standby equity purchase agreement (the “SEPA”) with YA II PN, LTD, a Cayman Islands
exempt limited partnership managed by Yorkville Advisors Global, LP (“Yorkville”). Pursuant to the SEPA, subject to certain
conditions, the Company has the option to sell to Yorkville an aggregate amount of up to $
Any
purchase under an advance would be subject to certain limitations, including that Yorkville will not purchase or acquire any shares that
would result in it and its affiliates beneficially owning more than % of the then outstanding voting power or number of shares of
Common Stock or any shares that when aggregated with shares issued under all other earlier advances, would exceed
| 13 |
In
connection with the execution of the SEPA, the Company paid a $
Additionally,
Yorkville agreed to advance to the Company, in exchange for a convertible promissory note (the “Yorkville Promissory Note”),
a principal amount of $
The Yorkville Promissory Note may be accelerated by Yorkville upon specified events of default, and may become amortizable for cash if (i) the daily VWAP is less than the Floor Price for five trading days during a period of seven consecutive trading days, (ii) the Company has issued in excess of 95% of the shares of Common Stock available under the Exchange Cap or (iii) the Company is in material breach of its obligations under a registration rights agreement it entered into with Yorkville in connection with the SEPA or Yorkville becomes limited in its ability to freely resell shares subject to an advance as further described in the Yorkville Promissory Note, subject to de-amortization after certain cures.
Yorkville Letter
On October 8, 2024, Yorkville sent the Company a letter notifying the Company that it had breached a registration rights agreement with Yorkville by failing to file a Registration Statement on Form S-1 on the timeline set forth in the registration rights agreement (the “Yorkville Letter”). The Yorkville Letter asserted that this breach was an event of default and an amortization event under the prepaid advance in connection with the SEPA. The Yorkville Letter also asserted that the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2024 was an event of default under the Yorkville Promissory Note. The Company subsequently engaged in discussions with Yorkville regarding the Yorkville Letter, which discussions are ongoing.
Pursuant to the Yorkville Promissory Note, upon the occurrence of an amortization event, the Company is required to pay all principal and accrued interest on the Yorkville Promissory Note, plus a 10% payment premium on the principal amount, in equal installments over 3 calendar months or until the amortization event is cured, whichever is earlier. In addition, upon the occurrence of an event of default, the interest rate on the Yorkville Promissory Note increases to 18% retroactive to the date of the event of default.
Executive Turnover
As previously announced on Form 8-K, on August 26, 2024, Lisa Embree, Chief Financial Officer, Executive Vice President, Treasurer and Secretary, notified the Company of her intention to resign from her position effective August 30, 2024.
Effective
August 30, 2024, the Board of Directors of the Company (the “Board”) appointed Mr. Robert Golden to serve as the Chief Financial
Officer (“CFO”) on an interim basis to fill the vacancy created by the resignation of Lisa Embree. Effective on his appointment
as interim CFO, Mr. Golden stepped down as a member and the chair of the Audit Committee of the Board. In connection with his appointment
as interim CFO, the Company entered into a consulting agreement with Mr. Golden, pursuant to which Mr. Golden will receive a $
As
previously announced on a Current Report on Form 8-K filed with the SEC on October 8, 2024, on October 1, 2024, Paul J. Casey and Erkan
Akyuz resigned from the Board, effective immediately. Also on October 1, 2024, the Board appointed Jair Clarke and Sherry Coonse McCraw
to the Board to fill the vacancies created by Mr. Casey and Mr. Akyuz, respectively. In connection with Ms. Coonse McCraw and Mr. Clarke’s
service on the Board, the Board approved an RSU grant providing for the grant of
| 14 |
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion and analysis are intended to help you understand our business, financial condition, results of operations, liquidity, and capital resources. You should read this discussion in conjunction with the Company’s consolidated financial statements and related notes included elsewhere in this Quarterly Report on Form 10-Q (this “Report”) and in the Form 10-K/A.
In addition to historical financial analysis, this discussion and analysis contains forward-looking statements based upon current expectations that involve risks, uncertainties, and assumptions, as described under the heading “Cautionary Note Regarding Forward Looking Statements.” Actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of various factors, risks and uncertainties, including those set forth under “Risk Factors” included elsewhere (or incorporated by reference) in this Report and in the Form 10-K/A. Unless the context otherwise requires, references in this “Management’s Discussion and Analysis of Financial Condition and Results of Operations” to “OneMedNet”, “we”, “us”, “our,” and “the Company” are intended to mean the business and operations of OneMedNet Corporation and its consolidated subsidiary following the Business Combination.
Company Overview
OneMedNet Corporation is a healthcare software company with solutions focused on digital medical image management, exchange, and sharing. The Company was founded in Delaware on November 20, 2015. The Company has been solely focused on creating solutions that simplify digital medical image management, exchange, and sharing. The Company has one wholly-owned subsidiary, OneMedNet Technologies (Canada) Inc., incorporated on October 16, 2015 under the provisions of the Business Corporations Act of British Columbia whose functional currency is the Canadian dollar. The Company’s headquarters location is Eden Prairie, Minnesota.
Business Combination
On November 7, 2023, we held the closing of the Business Combination whereby Merger Sub merged with and into Legacy ONMD, with Legacy ONMD continuing as the surviving entity, which resulted in all of the issued and outstanding capital stock of Legacy ONMD being exchanged for shares of Common Stock upon the terms set forth in the agreement and plan of merger, dated April 25, 2022 (the “Merger Agreement”), by and among Data Knights, Merger Sub, Legacy ONMD, Data Knights, LLC, a Delaware limited liability company (the “Sponsor”), and Paul Casey, in his capacity as representative of the stockholders of Legacy ONMD. The Business Combination and other transactions that closed on November 7, 2023, pursuant to the Merger Agreement, led to Data Knights changing its name to “OneMedNet Corporation” and the business of the Company became the business of Legacy ONMD.
Pursuant to the terms of the Merger Agreement, the total consideration for the Business Combination and related transactions (the “Merger Consideration”) was approximately $200 million. In connection with the special meeting of stockholders of Data Knights, certain public holders holding 1,600,741 shares of Data Knights common stock exercised their right to redeem such shares for a pro rata portion of the funds held by Continental Stock Transfer & Trust Company, as trustee in the trust account established in connection with Data Knights’ initial public offering. Effective November 7, 2023, Data Knights’ units ceased trading, and effective November 8, 2023, the Common Stock began trading on the Nasdaq Global Market under the symbol “ONMD” and the Public Warrants began trading on the Nasdaq Global Market under the symbol “ONMDW.” The Common Stock and Public Warrants were transferred from The Nasdaq Global Market to The Nasdaq Capital Market at the opening of business on August 19, 2024, and continue to trade under the symbols “ONMD” and “ONMDW,” respectively.
As a result of the Business Combination, holders of Data Knights common stock automatically received Common Stock of OneMedNet, and holders of Data Knights warrants automatically received warrants of OneMedNet with substantively identical terms. At the closing of the Business Combination, all shares of Data Knights owned by the Sponsor (consisting of shares of Data Knights common stock and shares of Data Knights Class B common stock), automatically converted into an equal number of shares of OneMedNet’s Common Stock, and the private placement warrants held by the Sponsor automatically converted into warrants to purchase one share of OneMedNet Common Stock with substantively identical terms.
| 15 |
Key Components of Consolidated Statements of Operations
Revenue
The Company generates revenue from two streams: (1) iRWD, which provides regulatory grade imaging and clinical data in the pharmaceutical, device manufacturing, contract research organizations, and AI markets and (2) BEAM, which is a medical imaging exchange platform between hospital/healthcare systems, imaging centers, physicians and patients. iRWD is sold on a fixed fee basis based on the number of data units and the cost per data unit committed to in the customer contract. Revenue is recognized when the data is delivered to the customer. BEAM revenue is subscription-based revenue that is recognized ratably over the subscription period committed to by the customer. The Company invoices its BEAM customers quarterly or annually in advance with the customer contracts automatically renewing unless the customer issues a cancellation notice.
The Company excludes from revenue taxes collected from a customer that are assessed by a governmental authority and imposed on and concurrent with a specific revenue-producing transaction. The transaction price for the products is the invoiced amount. Advanced billings from contracts are deferred and recognized as revenue when earned. Deferred revenue consists of payments received in advance of performance under the contract. Such amounts are generally recognized as revenue over the contractual period. The Company receives payments from customers based upon contractual billing schedules. Accounts receivable is recorded when the right to consideration becomes unconditional. Payment terms on invoiced amounts typically range from zero to 90 days, with typical terms of 30 days.
Cost of Revenue
Our cost of revenue is composed of our distinct performance obligations of hosting, labor, and data cost.
General and Administrative
General and administrative functions include finance, legal, human resources, operations, and information technology support. These functions include costs for items such as salaries and benefits and other personnel-related costs, maintenance and supplies, professional fees for external legal, accounting, and other consulting services, and depreciation expense.
Research and Development
Costs incurred in the research and development of our products are expensed as incurred. Research and development costs include personnel, contracted services, materials, and indirect costs involved in the design and development of new products and services, as well as hosting expense.
Sales and Marketing
Our sales and marketing costs consist of labor and tradeshow costs.
Interest Expense
Interest expense consists of interest incurred on shareholder loans.
Other (Income) Expenses, Net
Other (income) expenses, net, primarily includes the changes in fair value of convertible debt and change in fair value of PIPE Notes for which we have elected the fair value option of accounting. Convertible notes payable, which include convertible promissory notes and PIPE Notes issued to related parties, including accrued interest and contingently issuable warrants, contain embedded derivatives, including settlement of the contingent conversion features, which require bifurcation and separate accounting. Accordingly, we have elected to measure the entire contingently convertible debt instruments, including accrued interest, at fair value. These debt instruments were initially recorded at fair value as liabilities and are subsequently re-measured at fair value on our condensed consolidated balance sheet at the end of each reporting period and at settlement, as applicable. Other income or expenses, net, also includes changes in fair value of loan extensions, deferred underwriting fees and warrants which are treated as liability instruments measured at fair value for accounting purposes, initially recorded at fair value and subsequently re-measured to fair value on our condensed consolidated balance sheets at the end of each reporting period. The changes in the fair value of these debt and liability instruments are recorded in changes in fair value, included as a component of other (income) expenses, net, in the condensed consolidated statements of operations.
At the closing of the Business Combination, convertible promissory notes were converted into Common Stock immediately prior to the Closing and were no longer outstanding as of the closing date.
Other (income) expenses, net, also includes foreign exchange and tax expenses related to the Company’s operations and revenue outside of the United States.
| 16 |
Results of Operations
The following table sets forth our condensed consolidated statements of operations data for the periods presented:
Three Months Ended March 31, | Change | |||||||||||||||
| 2024 | 2023 | $ | % | |||||||||||||
| Revenue | ||||||||||||||||
| Subscription revenue | $ | 201 | $ | 167 | $ | 34 | 20 | % | ||||||||
| Web imaging revenue | 47 | 33 | 14 | 42 | % | |||||||||||
| Total revenue | 248 | 200 | 48 | 24 | % | |||||||||||
| Cost of revenue | 317 | 289 | 28 | 10 | % | |||||||||||
| Gross margin | (69 | ) | (89 | ) | 20 | -22 | % | |||||||||
| Operating expenses | ||||||||||||||||
| General and administrative | 1,358 | 539 | 819 | 152 | % | |||||||||||
| Sales and marketing | 229 | 259 | (30 | ) | -12 | % | ||||||||||
| Research and development | 445 | 582 | (137 | ) | -24 | % | ||||||||||
| Total operating expenses | 2,032 | 1,380 | 652 | 47 | % | |||||||||||
| Loss from operations | (2,101 | ) | (1,469 | ) | (632 | ) | 43 | % | ||||||||
| Other (income) expense, net | ||||||||||||||||
| Interest expense | 42 | - | 42 | N/A | ||||||||||||
| Change in fair value of warrants | (7 | ) | - | (7 | ) | N/A | ||||||||||
| Change in fair value of PIPE Notes | (20 | ) | - | (20 | ) | N/A | ||||||||||
| Change in fair value of convertible promissory notes | - | 4,414 | (4,414 | ) | -100 | % | ||||||||||
| Stock warrant expense | - | 1,935 | (1,935 | ) | -100 | % | ||||||||||
| Other (income) expense | (7 | ) | 8 | (15 | ) | -188 | % | |||||||||
| Total other (income) expenses, net | 8 | 6,357 | (6,349 | ) | -100 | % | ||||||||||
| Net loss | $ | (2,109 | ) | $ | (7,826 | ) | $ | 5,717 | -73 | % | ||||||
Revenue
Three Months Ended March 31, | Change | |||||||||||||||
| 2024 | 2023 | $ | % | |||||||||||||
| Subscription revenue (BEAM) | $ | 201 | $ | 167 | $ | 34 | 20 | % | ||||||||
| Web imaging revenue (iRWD) | 47 | 33 | 14 | 42 | % | |||||||||||
| Total | $ | 248 | $ | 200 | $ | 48 | 24 | % | ||||||||
Our revenue is comprised of sales made from our subscription revenue (BEAM) and from our web imaging (iRWD). For the three months ended March 31, 2024, overall revenue increased by 24%. The primary driver for the subscription revenue increase was delivery of revenue to a significant customer. The primary driver for the increase in web imaging revenue was revenue deliveries pushed to the first quarter of 2024.
Cost of Revenue
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| Cost of revenue | 317 | 289 | ||||||
| % of revenue | 128 | % | 145 | % | ||||
For the three months ended March 31, 2024, we were able to reduce our cost of revenue as a percentage of revenue by 17%. The decrease is primarily driven by lower iRWD consulting costs during the three months ended March 31, 2024.
| 17 |
General and Administrative
Our general and administrative expense increased $0.8 million, or 152%, to $1.4 million for the three months ended March 31, 2024 from $0.5 million for the three months ended March 31, 2023. The increase is primarily due to an increase in professional fees of $0.6 million from being a public company, employee salaries and benefits of $0.1 million and bad debt expense of $0.1 million.
Sales and Marketing
Our sales & marketing expense decreased $30 thousand, or 12%, to $229 thousand for the three months ended March 31, 2024 from $259 thousand for the three months ended March 31, 2023. The decrease is primarily due to a decrease in salaries and benefits of $84 thousand, which is partially offset by increases in trade shows, dues and subscriptions and consultants, which collectively increased by $54 thousand.
Research and development
Our research and development expense decreased $0.1 million, or 24%, to $0.5 million for the three months ended March 31, 2024 from $0.6 million for the three months ended March 31, 2023. The decrease is primarily due to a decrease in stock compensation expense of $0.2 million, which is partially offset by an increase in salaries and benefits of $0.1 million.
Interest Expense
During the three months ended March 31, 2024, interest expense was primarily comprised of interest expense on loans made from related parties (Management and Directors) and interest expense on $0.5 million of deferred underwriter fees payable in cash. During the three months ended March 31, 2023, we did not incur any interest expense.
Change in Fair Value of Warrants
The change in fair value of Warrants was due to the closing of the Business Combination and the resulting fluctuations in the market price of shares of Common Stock.
Change in Fair Value of PIPE Notes
The change in fair value of PIPE Notes was due to the closing of the Business Combination and the resulting fluctuations in the market price of shares of Common Stock.
Change in Fair Value of Convertible Debt
The change in fair value of convertible debt was due to the closing of the Business Combination and the resulting fluctuations of the market price of shares of Common Stock. The Convertible Promissory Notes were no longer outstanding during the three months ended March 31, 2024.
Non-GAAP Financial Measure
In addition to providing financial measurements based on U.S. GAAP, we provide an additional financial metric that is not prepared in accordance with U.S. GAAP (a “non-GAAP financial measure”). We use this non-GAAP financial measure, in addition to U.S. GAAP financial measures, to understand and compare operating results across accounting periods, for financial and operational decision making, for planning and forecasting purposes, to measure executive compensation, and to evaluate our financial performance. This non-GAAP financial measure is Adjusted EBITDA, as discussed below.
我們相信，這一非通用會計準則財務指標反映了我們業務的持續展開，使得可以進行有意義的比較和分析業務趨勢，因爲它有助於跨會計期間以及與同行公司的財務結果進行比較。我們還認爲，這一非通用會計準則財務指標使得投資者能夠評估我們的運營結果和未來前景，就像我們自己所做的那樣。這一非通用會計準則財務指標可能排除在性質上不同尋常、不時發生或不反映我們持續運營結果的費用和收益。
這個非美國通用會計準則財務指標不應被視爲美國通用會計準則財務指標的替代，可能與其他公司使用的同名非美國通用會計準則財務指標有所不同。此外，非美國通用會計準則財務指標存在侷限性，因爲它排除了必須包含在美國通用會計準則報告中的費用和收入。因此，非美國通用會計準則財務指標不能替代我們按照美國通用會計準則報告的財務指標，並且只能作爲我們根據美國通用會計準則呈報的財務業績的補充，而非替代品。美國通用會計準則淨損失是最接近的可比美國通用會計準則指標。
| 18 |
我們認爲調整後的EBITDA是衡量我們業務運營實力和表現的重要指標，也是衡量我們歷史經營趨勢的良好指標。調整後的EBITDA排除了我們不認爲是核心業務的項目。我們將調整後的EBITDA定義爲不包括以下項目的美國通用會計準則淨虧損：利息費用；所得稅費用；有形資產的折舊和攤銷；股份補償；業務合併交易費用；以及可能不時出現的其他非經常性項目。
非通用會計調整以及我們排除它們的非通用財務指標的依據如下：
| ● | 調整後的EBITDA不反映利息費用或股東貸款所需的現金支付，這並非我們業務的核心融資方式； | |
| ● | 調整後的EBITDA不反映與我們的外國子公司相關的所得稅費用，因爲自成立以來我們一直遭受整體運營虧損，並預計將來也會繼續如此； | |
| ● | 儘管折舊和攤銷是不計入現金的支出，但我們目前折舊和攤銷的資產未來可能需要更換，並且調整後的EBITDA不反映資金支出以滿足這種更換的需求； | |
| ● | 調整後的EBITDA不包括股權報酬費用，這對我們的業務是重要的一部分，且在可預見的未來將繼續是一項重大的經常性非現金支出，並且是我們薪酬策略的重要組成部分； | |
| ● | 調整後的EBITDA不反映由我們的管理層不認爲是我們持續經營的指示的收益或費用產生的影響。然而，其中一些費用和收益（如市場調整、股票認股權費用等）是反覆出現且可能會再次出現；和 | |
| ● | 其他公司，包括我們行業的公司，可能以不同方式計算調整後的EBITDA，這降低了其作爲比較指標的實用性。 |
下表對比了美國公認會計原則（GAAP）淨虧損與調整後的EBITDA在所呈現期間的 reconciliation（單位：千美元）：
| 截至3月31日的三個月結束 | ||||||||
| 2024 | 2023 | |||||||
| 淨虧損 | $ | (2,109 | ) | $ | (7,826 | ) | ||
| 利息支出 | 42 | - | ||||||
| 折舊和攤銷 | 11 | 6 | ||||||
| 基於股票的補償 | 137 | 368 | ||||||
| 認股權證公允價值變動 | (7 | ) | - | |||||
| PIPE票據公平值變動 | (20 | ) | - | |||||
| 可轉換應收票據公平價值變動 | - | 4,414 | ||||||
| 存貨權證費用 | - | 1,935 | ||||||
| 調整後的EBITDA | (1,946 | ) | (1,103 | ) | ||||
流動性和資本資源
截至2024年3月31日，我們的主要流動資金來源是來自關聯方投資者的收益、循環信貸額度以及客戶支付的現金。
下表顯示了所列期間內用於經營活動的淨現金及現金等價物、用於投資活動的淨現金及現金等價物，以及通過融資活動提供的淨現金及現金等價物：
| 截至3月31日的三個月結束 | ||||||||
| 2024 | 2023 | |||||||
| 經營活動產生的淨現金流量 | ||||||||
| 經營活動 | $ | (1,547 | ) | $ | (1,002 | ) | ||
| 投資活動 | (6 | ) | - | |||||
| 籌資活動 | 1,680 | 876 | ||||||
| 19 |
運營活動
我們的 在經營活動中使用的淨現金及現金等價物包括經調整後的淨損失，該損失考慮了某些非現金項目，包括折舊 和攤銷、基於股票的薪酬費用、分類爲負債的金融工具的公允價值變動，以及 經營資產和負債的變動。流動資本項目的主要變化，如應收賬款 和遞延收入的變化，源於客戶與我們之間合同履行義務支付時間的差異。 這可能導致在此期間操作現金流的來源或使用，取決於所收到的款項支付時間與 履行履行義務的比較。
截至2024年3月31日的三個月內，經營活動淨現金使用爲150萬美元。經營活動淨現金使用 是由於我們210萬美元的淨虧損，這被100000美元的非現金項目抵消，主要包括基於股票的補償， 以及由於向供應商付款時間和客戶收款時間的現金流動情況造成的40萬美元的經營資產和負債的現金。
相比之下，公司在截至2023年3月31日的三個月內，運營活動使用的淨現金爲100萬美元。 截至2023年3月31日的三個月內，運營活動使用的淨現金是由於我們的淨虧損爲780萬美元， 這一虧損被非現金項目670萬美元抵消，主要包括可轉換債務公允價值變化440萬美元、股票期權支出190萬美元和股票基礎補償支出40萬美元，以及由於向供應商支付現金和從客戶收取現金的時間安排導致的運營資產和負債的現金爲0.1萬美元。
投資活動
我們的投資活動主要包括房地產和設備購買。
2024年3月31日三個月期間用於投資活動的淨現金及現金等價物包括0.6萬美元的購買房地產和設備。
相比之下，在截至2023年3月31日的三個月期間，沒有現金及現金等價物被用於或提供給投資活動。
融資活動
2024年3月31日結束的三個月，融資活動提供的淨現金爲170萬美元，主要包括相關方貸款的130萬美元和循環信貸的40萬美元。
相比之下，公司在截至2023年3月31日的三個月內通過融資活動提供的淨現金爲90萬美元，主要由110萬美元的可轉換票據發行所得抵消20萬美元的業務組合費用。
合同 義務和承諾及持續經營展望
目前，管理層認爲我們的現金及現金等價物不足以滿足我們在未來12個月內可預見的現金需求。除了我們的經常性營業費用外，我們的可預見現金需求還包括支持我們製造行業和員工擴張的預期資本支出、利息費用和最低合同義務。管理層打算通過債務和股權發行來籌集運營所需的現金。因此，由於公司經常性經營虧損以及對資金的額外需求來支持其營業和資本要求，存在關於公司能否維持足夠流動性的重大不確定性，這使得公司持續經營的能力受到相當大的懷疑。
我們未來的資本需求將取決於許多因素，包括我們的增長率、支持研究和開發工作的支出時機和範圍、銷售和市場活動的擴展、新產品和服務的推出與提升，以及未來收購科技或企業的成本。如果需要外部融資，我們可能無法在可接受的條件下籌集所有基金類型，甚至可能根本無法籌集。
| 20 |
以下表格總結了截至2024年3月31日我們當前和開多期的現金需求：
| 應付款項： | ||||||||||||
| 總計 | 少於1年 | 1-3年 | ||||||||||
| 應付賬款和應計費用 | $ | 5,874 | $ | 5,874 | $ | - | ||||||
| 貸款延期 | 2,992 | 2,992 | - | |||||||||
| 應付的承銷商費用 | 3,307 | 3,307 | - | |||||||||
| 關聯方借款 | 1,777 | - | 1,777 | |||||||||
| PIPE 註記 | 1,617 | 1,617 | - | |||||||||
| 授信額度 | 411 | 411 | - | |||||||||
| $ | 15,979 | $ | 14,202 | $ | 1,777 | |||||||
關鍵會計政策和估計
我們的 管理層對財務狀況和運營結果的討論與分析是基於我們的綜合財務 報表，這些報表是根據一般公認會計原則（GAAP）編制的。在準備我們的基本報表時，我們做出了估計、假設和 判斷，這些因素可能會對我們的營業收入、運營結果以及淨利潤或虧損產生顯著影響，也會影響到 我們的資產負債表上某些資產和負債的價值，這些是在報告期間內及截至報告期時的情況。這些估計、假設和 判斷是必要的，因爲未來事件及其對我們運營結果和資產價值的影響無法確定，並且是基於我們的歷史經驗以及其他我們認爲在這種情況下合理的假設進行的。 隨着新事件的發生或獲取更多信息，這些估計可能會改變，我們可能會定期面臨不確定性， 這些不確定性的結果不在我們的控制範圍內，可能會在較長一段時間內無法得知。由於在財務報告過程中使用估計是固有的，實際結果可能與這些估計有所不同。
有關我們關鍵會計估計的討論，請參見在10-K/A表格中的「管理層討論與財務狀況及經營成果分析」，以及在10-K/A表格中所列的審計基本報表的附註，和本報告其他地方所包含的基本報表附註。到2024年3月31日，這些關鍵會計政策和估計沒有發生重大變化，和在10-K/A表格中討論的內容一致。
最近發佈和採用的會計原則
最近發佈的會計公告的描述，可能會影響我們的財務狀況和經營業績，已在本報告其他部分的註釋2中披露，包含在我們的合併基本報表中。
項目3. 關於市場風險的定量和定性披露
我們是一家受到Exchange Act規則12b-2定義爲較小報告公司的公司，不需要提供此項目要求的信息。
物品 4。控制和程序
披露控制和程序的評估
我們的管理層在首席執行官和首席財務官的參與下，評估了截至2024年3月31日我們的披露控制和程序的設計和控件的有效性（根據證券交易法第13a-15(e)和15d-15(e)條款的定義）。基於該評估，首席執行官和首席財務官得出結論，截至2024年3月31日，我們的披露控制和程序並不有效，因爲我們的財務報告內部控制存在重大缺陷，未能正確設計，以確保能妥善識別非常規交易並確保適當的職責劃分。
材料 軟弱
如本報告其他部分所述，我們於2023年11月7日完成了業務合併。在業務合併之前，我們的前身Data Knights是一家特殊目的收購公司，成立的目的是進行與一家或多家企業的合併、資本股票交換、資產收購、股票購買、資本重組或類似業務結合。因此，之前的內部控制在評估日期時不再適用或不夠全面，因爲在業務合併之前，Data Knights的運營與合併後實體的運營相比微不足道。因此，管理層意識到公司內部控制在用戶訪問/職責分離、缺乏正式控制環境和對財務報告控件的監督、在非例行交易中的會計錯誤以及缺乏記錄保存方面存在重大缺陷。由於目前經驗的成交量有限，加上我們的財務限制，我們目前沒有擴展的會計部門來更好地分離職責。隨着時間的推移，隨着我們繼續增長並增加會計人員，我們預計將持續增強我們的內部控制結構，包括適當的職責分離。在2024年9月，進行了會計人員的變更，以增強我們的財務報告結構，我們預計這將減輕報告壓力，包括非例行交易的報告。此外，新人員專注於創建中央檔案庫來管理會計記錄和其他公司文件。
基本報表的控件內部審計控制的變化。
截至2024年3月31日結束的三個月內，我們的財務報告內部控制沒有發生任何變化，這些變化可能對我們的內部控制有實質性影響，或者有可能對我們的內部控制產生實質性影響。
| 21 |
PART II - 其他信息
項目1。法律訴訟
我們 可能不時會面臨各種索賠、訴訟和其他因正常 業務而產生的法律和行政程序。這些索賠、訴訟和其他程序中的一些可能涉及高度複雜的問題，這些問題存在着實質性的不確定性， 並可能導致損害賠償、罰款、處罰、非貨幣制裁或救濟。目前我們沒有參與任何法律程序， 在管理層看來，如果對我們不利的裁決將單獨或合併對我們的業務、經營結果、財務狀況或現金流產生重大不利影響。
事項1A.風險因素。
除了本報告中列出的其他信息外，您還應仔細考慮在10-K/A表格和我們其他公開文件中討論的「風險因素」，這些因素可能對我們的業務、財務控件或未來業績產生重大影響。此前在10-K/A表格和我們其他公開文件中的「風險因素」中沒有發生重大變化。
如果您還未使用您的moomoo帳戶，請使用它查看該功能。
2024年3月31日結束的三個月內，我們沒有銷售未在《8-k表格》中事先包括的未註冊證券。
項目3. 對高級證券的違約。
無。
項目4. 煤礦安全披露。
不適用。
項目5. 其他信息。
在2024年3月31日結束的三個月中，公司的任何董事或高管
項目 6. 附件。
本季度報告（表格10-Q）附帶的文件如下：
隨附提交。
# 附在本季度報告表格10-Q中的附件32.1和附件32.2所提供的認證被視爲附隨此報告，並且 不應被視爲爲1934年證券交易法第18節所規定的「提交」，除非 註冊人特別通過引用將其納入。
| 22 |
簽名
根據1934年證券交易法的要求，註冊人已正式授權下述簽署人員於2024年12月5日代表其簽署本報告。
| OneMedNet公司 | ||
| 由： | /s/ 羅伯特·戈爾登 | |
| 羅伯特 戈爾登 | ||
| 臨時首席財務官 （授權官員和信安金融及會計官員） | ||
| 23 |